
Absci Corp (ABSI) Stock Forecast & Price Target
Absci Corp (ABSI) Analyst Ratings
Bulls say
Absci Corp's innovative approach to biologic drug discovery, notably through its AI-powered synthetic biology platform, positions the company favorably in the therapeutics market with the potential for significant growth in the creation of novel biologics. The management's projection of a target hair growth of at least 40 hairs/cm² for ABS-201 is deemed highly competitive, with an increased rNPV to $1.6 billion indicating strong financial potential based on the forthcoming efficacy data from the MAD study. The heightened interest in ABS-201, illustrated by substantial consumer demand for in-office procedures, further underscores the anticipated positive trajectory of the company’s product pipeline and market positioning.
Bears say
The analysis indicates several risks that could hinder the performance of Absci Corp's stock, including challenges in partnerships, technology, and regulatory approvals, which are essential for the company's success in the competitive synthetic biology market. Additionally, the lack of strong standard of care in endo for non-hormonal treatment options, coupled with a high treatment burden leading patients to seek alternative solutions, may limit market penetration and revenue potential. Furthermore, concerns regarding intellectual property and possible dilution add to the uncertainties facing Absci, negatively impacting investor confidence and outlook.
This aggregate rating is based on analysts' research of Absci Corp and is not a guaranteed prediction by Public.com or investment advice.
Absci Corp (ABSI) Analyst Forecast & Price Prediction
Start investing in Absci Corp (ABSI)
Order type
Buy in
Order amount
Est. shares
0 shares